In the latest close session, Merck (MRK) was down 1.95% at $121.41. This move lagged the S&P 500's daily gain of 0.04%. Meanwhile, the Dow experienced a drop of 0.15%, and the technology-dominated ...

A giant in the healthcare space, Merck (NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail ...

Merck & Co. shares clocked seven straight sessions of gains, as the stock was up 0.2% at $124.1 on Tuesday. The global healthcare company gained 2% in the preceding six sessions.

Shares of Merck & Co. Inc. MRK slipped 1.30% to $119.83 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.94% to 6,816.63 ...

Tempus AI expands its Merck deal as markets slide. Analysts stay bullish, but the stock trades near 52-week lows.

Merck isn't exciting in the same way as GLP-1 leader Eli Lilly. But it presents an opportunity for investors who use ...

The drugmaker is splitting up its Human Health business before patent protection on its blockbuster treatment Keytruda expires in two years.

We recently published 8 Stocks on Jim Cramer’s Radar. Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s radars. Pharma giant Merck & Co., Inc. (NYSE:MRK)’s shares are up by 1.9% ...

Merck (NYSE:MRK) announced a major reorganization of its Human Health business into two global units focused on Oncology and ...